Lung Cancer Complications

Post-obstructive pneumonia, malignant pleural effusion, hemoptysis, airway obstruction, and SVC syndrome — common inpatient admissions in lung cancer patients

Symptoms / Associated Sx

• Post-obstructive pneumonia: Fever + productive cough + same-lobe recurrent pneumonia; partial or complete bronchial obstruction by tumor

• Malignant pleural effusion: Progressive dyspnea; dullness + absent breath sounds at base; unilateral large effusion

• Hemoptysis: Bright red blood (see hemoptysis section)

• Central airway obstruction: Stridor, severe dyspnea, wheeze, respiratory failure; tumor in trachea or main bronchi

• SVC syndrome: Facial/neck/arm swelling; JVD; collateral veins on chest wall; Pemberton's sign (raising arms → facial flushing); headache; altered mentation (severe)

Denies

• Prior pneumonia in same location resolving completely (raises post-obstructive concern if recurrent same lobe)

• Bilateral symmetric effusion (reduces malignant; raises CHF or hypoalbuminemia)

• Upper extremity DVT without SVC involvement (SVC syndrome has specific distribution of swelling — bilateral facial + upper extremity)

Social History (SHx)

Smoking history (NSCLC most common), lung cancer type and stage, current oncologic treatment (chemotherapy, targeted therapy, immunotherapy, radiation), prior radiation to chest (radiation fibrosis, pericarditis), performance status, prior thoracoscopy/biopsy, EGFR/ALK/PD-L1 mutation status.

Main Etiology

• NSCLC (adenocarcinoma, squamous cell, large cell) — ~85% of lung cancers

• SCLC — rapidly growing; SVC syndrome most common with SCLC (mediastinal involvement)

• Endobronchial obstruction → post-obstructive pneumonia (distal to tumor; mixed flora including anaerobes)

• Pleural seeding → malignant effusion (exudative; bloody; cytology positive in ~60%)

• Tumor or mediastinal lymphadenopathy → SVC compression → SVC syndrome

Most Common DDx

• Simple community-acquired pneumonia without obstruction (responds to standard antibiotics; different lobe or bilateral; no underlying mass)

• CHF effusion (bilateral; transudative; elevated BNP; responds to diuresis)

• Superior vena cava thrombosis without malignancy (central venous catheter-related; hypercoagulable state; no mass on CT)

• Lymphoma causing SVC syndrome (young patient; mediastinal mass; lymph node biopsy; SVC syndrome with non-lung primary)

• Empyema rather than simple parapneumonic (pH <7.2; positive culture; requires drainage)

• Pleural mesothelioma (diffuse pleural thickening; asbestos exposure; CT characterization; pleural biopsy)

DATA

• CBC (leukocytosis — infection; anemia — malignancy)

• BMP (electrolytes; calcium — hypercalcemia of malignancy; creatinine)

• LFTs (liver mets; albumin)

• CT chest/abdomen/pelvis with contrast (staging; characterize obstruction, effusion, mediastinal involvement)

• CT with SVC protocol (SVC syndrome — 3D reconstruction of SVC anatomy)

• Bronchoscopy (direct visualization of endobronchial obstruction; biopsy; debulking; stent placement)

• Thoracentesis + cytology (malignant effusion — sensitivity ~60%; repeat if negative + high suspicion; cell block improves yield)

• MRI (brain mets if neurologic symptoms; MRI chest if superior sulcus tumor)

• PET scan (staging; restaging)

• Molecular profiling (EGFR, ALK, ROS1, KRAS, BRAF, PD-L1 — essential for targeted therapy selection)

• Sputum cytology + culture (post-obstructive pneumonia)

Home Meds

• Current oncologic therapy (checkpoint inhibitors — pneumonitis risk; TKIs — pulmonary toxicity risk; chemotherapy — myelosuppression)

• Anticoagulants (malignancy-associated VTE; assess type and dose)

• Steroids (dexamethasone for SVC syndrome, brain mets, or immunotherapy toxicity)

Plan

• Post-obstructive pneumonia:

  • Broad-spectrum antibiotics covering gram-negatives + anaerobes: Piperacillin-tazobactam 3.375 g IV q6h × 7–14 days; step-down to Amoxicillin-clavulanate PO after improvement

  • Bronchoscopy (direct visualization + debulking of endobronchial tumor; laser ablation, APC, or stent placement)

  • Oncology-directed therapy to shrink tumor (chemotherapy, targeted therapy, radiation)

  • Chest physiotherapy; mucolytics; bronchodilators

• Malignant pleural effusion:

  • Therapeutic thoracentesis (≤1500 mL at a time) for symptomatic relief

  • Tunneled pleural catheter (PleurX) — preferred for recurrent malignant effusion; outpatient drainage 3× per week

  • Chemical pleurodesis (talc slurry via chest tube OR talc poudrage at VATS): if lung fully re-expands and patient expected to survive >1–3 months

  • Do NOT attempt pleurodesis in trapped lung (lung tethered and cannot expand)

• Central airway obstruction:

  • Interventional bronchoscopy (rigid bronchoscopy preferred): tumor debulking (APC, laser, cryotherapy, electrocautery); endobronchial stent placement

  • External beam radiation (EBRT) for sensitive tumors (SCLC, squamous cell)

  • Intraluminal brachytherapy (HDR)

  • If imminent respiratory failure from obstruction → rigid bronchoscopy as emergency

• SVC syndrome:

  • Elevate head of bed (reduces venous pressure); supplemental O2

  • Dexamethasone 10 mg IV × 1 → 4 mg IV q6h (reduces peritumoral edema — especially SCLC)

  • Endovascular SVC stenting (IR — fastest symptom relief; first-line for life-threatening SVC syndrome with airway/neurologic compromise)

  • Radiation therapy (SCLC most responsive; NSCLC palliative XRT)

  • Chemotherapy (SCLC — rapid response; first-line systemic treatment)

  • Anticoagulation: therapeutic if SVC thrombosis documented (LMWH preferred in malignancy)

  • Avoid IVs in upper extremities (poor venous return)

• Oncology consult for all complications; pulmonology/interventional pulmonology for airway complications

• Palliative care referral early (lung cancer complications → performance status declining)

• Daily CBC, BMP, calcium; CXR; O2 monitoring

• PT/OT — energy conservation; mobility

• Discharge: PleurX catheter care education; antibiotic course completion; dexamethasone taper (SVC syndrome); outpatient oncology within 1 week; interventional pulmonology follow-up if stent placed; advance directives discussion; hospice referral if stage IV with declining PS

Red Flags

• Stridor + respiratory failure from central airway obstruction → rigid bronchoscopy emergency; cannot intubate below obstruction; call interventional pulmonology + thoracic surgery immediately

• SVC syndrome + cerebral edema (confusion, papilledema) → immediate SVC stenting; life-threatening neurologic compromise

• Massive hemoptysis from tumor → position bleeding-side down; rigid bronchoscopy; BAE; thoracic surgery (see hemoptysis section)

• Spinal cord compression from lung cancer mets (back pain + neurologic deficits) → dexamethasone IV immediately + MRI spine STAT + radiation/neurosurgery

• Post-obstructive pneumonia not improving → repeat CT; bronchoscopy; consider resistant organism or abscess

Senior IM Resident Pearls

• Post-obstructive pneumonia in same lobe = malignancy until proven otherwise — any pneumonia that recurs in the same anatomic distribution requires CT chest + bronchoscopy; do not discharge without arranging workup

• SVC syndrome is NOT always an emergency — chronic SVC syndrome can present subacutely; only urgent stenting needed when: stridor, severe cerebral edema, cardiac compromise, or rapidly progressive symptoms

• PleurX tunneled catheter vs. pleurodesis: If lung is trapped (does not re-expand after thoracentesis) → pleurodesis cannot work (lung won't appose chest wall) → PleurX catheter for long-term drainage; if lung fully expands → pleurodesis is curative in ~70%

• Molecular profiling (EGFR, ALK, PD-L1) is essential before starting systemic therapy in stage IV NSCLC — targeted therapy (osimertinib for EGFR) and immunotherapy (pembrolizumab for high PD-L1) dramatically improve outcomes vs. chemotherapy in selected patients

• Common mistake: IV access in upper extremity with SVC syndrome — all IVs must go in lower extremity (femoral) or central access below the obstruction; upper extremity IVs will not deliver medication to central circulation